04.03.2013 • NewsDowDow ChemicalKuwait

Arbitrator Sets Final Dow Chemical Payout from Kuwait Venture

Dow Chemical said an arbitrator has ruled it is owed $2.48 billion by a Kuwaiti firm that scuttled a 2008 joint venture, though it is not clear when the funds will be paid.

The company had expected at least $2.16 billion, and on Monday the International Court of Arbitration of the International Chamber of Commerce ruled at least $318 million in interest and other fees should be added to the amount, Dow Chemical said in a statement.

In late 2008 Dow planned a $17.4 billion joint venture with Petrochemical Industries (PIC) of Kuwait, spinning off its basics plastics business into a standalone company called K-Dow.

PIC pulled out of the deal in December 2008, citing a deteriorating global economy. An arbitrator ruled last year that PIC was at fault and owed Dow Chemical $2.16 billion, plus interest and costs.

Dow said the decision finalizes the amount in interest and fees Dow Chemical can expect, but it is unclear when the company will receive payment.

PIC, a unit of the Kuwait Petroleum Corp, was not immediately available to comment.

"We are resolved to take appropriate action to ensure timely payment," Dow spokeswoman Nancy Lamb said. She would not elaborate on what action Dow Chemical could take.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.